SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-19-299849
Filing Date
2019-11-25
Accepted
2019-11-25 16:07:02
Documents
12
Period of Report
2019-11-20
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.05: Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics

Document Format Files

Seq Description Document Type Size
1 8-K d839404d8k.htm   iXBRL 8-K 45287
  Complete submission text file 0001193125-19-299849.txt   167385

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA fprx-20191120.xsd EX-101.SCH 3075
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE fprx-20191120_lab.xml EX-101.LAB 17376
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fprx-20191120_pre.xml EX-101.PRE 10957
10 EXTRACTED XBRL INSTANCE DOCUMENT d839404d8k_htm.xml XML 3258
Mailing Address 111 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 111 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 415-365-5600
FIVE PRIME THERAPEUTICS, INC. (Filer) CIK: 0001175505 (see all company filings)

IRS No.: 260038620 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36070 | Film No.: 191246202
SIC: 2834 Pharmaceutical Preparations